We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
- Recent AXSM Stock Price: $40.64
- Yearly Gain for AXSM stock: -38.46%
- Market Cap for AXSM stock: $1.58B
- P/E Ratio for AXSM stock: -10.929
Will AXSM's stock price go up? Is there an accurate AXSM stock forecast available?
TipRanks.com reports that Axsome Therapeutics currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $65.44. The target pricing ranges from a high AXSM forecast of $130.00 down to a low forecast of $27.00. Axsome Therapeutics (AXSM)’s last closing stock price was $40.64 which would put the average price target at 61.02% upside.
In addition, TradingView issued a Buy rating for AXSM stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AXSM stock.
Other analysts covering AXSM include:
- Jason Gerberry of Bank of America Securities issued a Sell rating with the price target of $ 28 on 6 days ago
- Marc Goodman of SVB Securities issued a Buy rating with the price target of n/a on 6 days ago
- Joseph Thome of Cowen & Co. issued a Buy rating with the price target of $ 130 on 6 days ago
- Chris Howerton of Jefferies issued a Buy rating with the price target of $ 77 on 1 week ago
If you are wondering if AXSM is a good stock to buy, here are 3rd party ratings for AXSM stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Axsome Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for AXSM stock: Bullish
- Blogger Consensus for AXSM stock: Bullish
- Media Buzz for AXSM stock: High
- Insider Signal for AXSM stock: ―
- Investor Sentiment for AXSM stock: Neutral
- Hedge Fund signal for AXSM stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on AXSM stock including scouring the social networks like AXSM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AXSM stock chart >>
Summary: Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
- Recent BPMC Stock Price: $49.93
- Yearly Gain for BPMC stock: -41.96%
- Market Cap for BPMC stock: $2.97B
- P/E Ratio for BPMC stock: -4.52
Will BPMC's stock price go up? Is there an accurate BPMC stock forecast available?
TipRanks.com reports that Blueprint Medicines currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $79.78. The target pricing ranges from a high BPMC forecast of $152.00 down to a low forecast of $40.00. Blueprint Medicines (BPMC)’s last closing stock price was $49.93 which would put the average price target at 59.78% upside.
In addition, TradingView issued a n/a rating for BPMC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BPMC stock.
Other analysts covering BPMC include:
- Christopher Raymond of Piper Sandler issued a Hold rating with the price target of n/a on 5 days ago
- Joel Beatty of Robert W. Baird issued a Buy rating with the price target of $ 96 on 5 days ago
- Andrew Berens of SVB Securities issued a Hold rating with the price target of $ 56 on 5 days ago
- Bradley Canino of Stifel Nicolaus issued a Buy rating with the price target of $ 90 on 5 days ago
If you are wondering if BPMC is a good stock to buy, here are 3rd party ratings for BPMC stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Blueprint Medicines? (Current ratings compiled by TipRanks.com)
- News Sentiment for BPMC stock: Very Bullish
- Blogger Consensus for BPMC stock: ―
- Media Buzz for BPMC stock: Low
- Insider Signal for BPMC stock: Negative
- Investor Sentiment for BPMC stock: Negative
- Hedge Fund signal for BPMC stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on BPMC stock including scouring the social networks like BPMC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BPMC stock chart >>
Summary: Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
- Recent ROIV Stock Price: $4.42
- Yearly Gain for ROIV stock: -55.35%
- Market Cap for ROIV stock: $3.10B
- P/E Ratio for ROIV stock: -1.302
Will ROIV's stock price go up? Is there an accurate ROIV stock forecast available?
TipRanks.com reports that Roivant Sciences currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.83. The target pricing ranges from a high ROIV forecast of $16.00 down to a low forecast of $6.00. Roivant Sciences (ROIV)’s last closing stock price was $4.42 which would put the average price target at 145.02% upside.
In addition, TradingView issued a Buy rating for ROIV stock over the next month, Barchart.com has a n/a rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ROIV stock.
Other analysts covering ROIV include:
- Dennis Ding of Jefferies issued a Buy rating with the price target of $ 16 on 6 days ago
- Robyn Karnauskas of Truist Financial issued a Buy rating with the price target of $ 13 on 1 week ago
- David Risinger of SVB Securities issued a Buy rating with the price target of $ 7 on 1 week ago
- Neena Bitritto-Garg of Citigroup issued a Buy rating with the price target of $ 9 on 1 week ago
If you are wondering if ROIV is a good stock to buy, here are 3rd party ratings for ROIV stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Roivant Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for ROIV stock: Very Bullish
- Blogger Consensus for ROIV stock: ―
- Media Buzz for ROIV stock: Very High
- Insider Signal for ROIV stock: Negative
- Investor Sentiment for ROIV stock: Very Negative
- Hedge Fund signal for ROIV stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ROIV stock including scouring the social networks like ROIV StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ROIV stock chart >>
Summary: BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.
- Recent BNTX Stock Price: $157.50
- Yearly Gain for BNTX stock: -29.01%
- Market Cap for BNTX stock: $38.28B
- P/E Ratio for BNTX stock: 2.562
Will BNTX's stock price go up? Is there an accurate BNTX stock forecast available?
TipRanks.com reports that BioNTech SE currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $236.70. The target pricing ranges from a high BNTX forecast of $350.00 down to a low forecast of $168.00. BioNTech SE (BNTX)’s last closing stock price was $157.50 which would put the average price target at 50.29% upside.
In addition, TradingView issued a Buy rating for BNTX stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BNTX stock.
Other analysts covering BNTX include:
- Chris Shibutani of Goldman Sachs issued a Hold rating with the price target of $ 209 on 6 days ago
- Eliana Merle of UBS issued a Hold rating with the price target of $ 168 on 6 days ago
- Zhiqiang Shu of Berenberg Bank issued a Buy rating with the price target of $ 350 on 1 week ago
- Robert Burns of H.C. Wainwright issued a Buy rating with the price target of $ 298 on 2 weeks ago
If you are wondering if BNTX is a good stock to buy, here are 3rd party ratings for BNTX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding BioNTech SE? (Current ratings compiled by TipRanks.com)
- News Sentiment for BNTX stock: Very Bullish
- Blogger Consensus for BNTX stock: Bullish
- Media Buzz for BNTX stock: Medium
- Insider Signal for BNTX stock: ―
- Investor Sentiment for BNTX stock: Negative
- Hedge Fund signal for BNTX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on BNTX stock including scouring the social networks like BNTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BNTX stock chart >>
Summary: 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.
- Recent ETNB Stock Price: $3.24
- Yearly Gain for ETNB stock: -81.42%
- Market Cap for ETNB stock: $126.45M
- P/E Ratio for ETNB stock: -0.648
Will ETNB's stock price go up? Is there an accurate ETNB stock forecast available?
TipRanks.com reports that 89bio currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $26.25. The target pricing ranges from a high ETNB forecast of $50.00 down to a low forecast of $14.00. 89bio (ETNB)’s last closing stock price was $3.24 which would put the average price target at 710.19% upside.
In addition, TradingView issued a n/a rating for ETNB stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ETNB stock.
Other analysts covering ETNB include:
- Steven Seedhouse of Raymond James issued a Buy rating with the price target of $ 14 on 6 days ago
- Justin Zelin of BTIG issued a Buy rating with the price target of $ 24 on 1 week ago
- Brian Abrahams of RBC Capital issued a Buy rating with the price target of $ 32 on 1 week ago
- Geoff Meacham of Bank of America Securities issued a Buy rating with the price target of n/a on 1 month ago
If you are wondering if ETNB is a good stock to buy, here are 3rd party ratings for ETNB stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding 89bio? (Current ratings compiled by TipRanks.com)
- News Sentiment for ETNB stock: Very Bullish
- Blogger Consensus for ETNB stock: Bullish
- Media Buzz for ETNB stock: High
- Insider Signal for ETNB stock: ―
- Investor Sentiment for ETNB stock: Very Positive
- Hedge Fund signal for ETNB stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ETNB stock including scouring the social networks like ETNB StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ETNB stock chart >>
Summary: Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California.
- Recent KZR Stock Price: $9.29
- Yearly Gain for KZR stock: 73.32%
- Market Cap for KZR stock: $561.26M
- P/E Ratio for KZR stock: -8.883
Will KZR's stock price go up? Is there an accurate KZR stock forecast available?
TipRanks.com reports that Kezar Life Sciences currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.67. The target pricing ranges from a high KZR forecast of $22.00 down to a low forecast of $17.00. Kezar Life Sciences (KZR)’s last closing stock price was $9.29 which would put the average price target at 111.73% upside.
In addition, TradingView issued a Buy rating for KZR stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on KZR stock.
Other analysts covering KZR include:
- Derek Archila of Wells Fargo issued a Buy rating with the price target of $ 17 on 1 week ago
- Catherine Novack of JonesTrading issued a Buy rating with the price target of n/a on 1 week ago
- Ram Selvaraju of H.C. Wainwright issued a Buy rating with the price target of $ 22 on 1 week ago
- Matt Phipps of William Blair issued a Buy rating with the price target of n/a on 1 month ago
If you are wondering if KZR is a good stock to buy, here are 3rd party ratings for KZR stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 39% (98 out of 251)
What is the sentiment on the street regarding Kezar Life Sciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for KZR stock: Very Bullish
- Blogger Consensus for KZR stock: ―
- Media Buzz for KZR stock: Very High
- Insider Signal for KZR stock: ―
- Investor Sentiment for KZR stock: Very Positive
- Hedge Fund signal for KZR stock: Positive
The stock market is extremely volatile, and you need to do your own research on KZR stock including scouring the social networks like KZR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for KZR stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================